LYCOS RETRIEVER 
Wyeth: Companies
built 816 days ago
Given the success of the Early Adopter pilot, Wyeth is now moving forward aggressively with a global upgrade to GroupWise 6.5. The company anticipates that the upgrade will significantly improve user productivity with new features that will enable clients to organize large amounts of e-mail and keep junk mail under control.
Source:
Biotica has granted Wyeth worldwide rights to its most advanced drug candidates, a portfolio of additional rapamycin analogs, and the technology to discover new compounds. The companies will collaborate on a multiproduct discovery program from which compounds will be selected for development and commercialization by Wyeth. Biotica will receive an initial payment, research support, and milestone payments. Potential payments to Biotica could total up to $195 million for the successful development and commercialization of multiple products. In addition, Biotica will receive royalties on product sales.
Source:
Euromonitor International's company profile, Wyeth offers detailed strategic analysis of the company's business, examining its performance in the otc healthcare market. The report examines company shares by region and sector, brand portfolio and new product developments, market and distribution strategies, challenges from the competition and future prospects. Use it to understand opportunities and threats facing the business and the factors driving success .
Source:
BEAUMONT, Texas, April 27 /PRNewswire/ -- The following was released today by Majority Counsel: A Beaumont, Texas jury today returned a more than $1 billion verdict against Wyeth-Ayerst Laboratories in a landmark Fen-Phen trial. Experts predict that this outcome against drug-maker Wyeth will set the standard by which the company will be judged in the tens of thousands of Fen-Phen cases currently in the court system awaiting trial dates.
Source:
In Taiwan, company reps donate other products to shops providing increased shelf space to Wyeth products. The company ... gives shops discounts for sales volume and bonuses to staff for extra shelf space.
Source:
That's not all the bad news for Wyeth today. In yet another blow, the company and its partner ViroPharma have stopped dosing patients with HCV-796, a Phase II hepatitis C drug candidate. The decision
Source:
MORE ABOUT
Companies